rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Recent evidence associates the codon 12 valine-for-glycine (G12V) mutant Ki-Ras protein with higher stage and increased lethality of colorectal carcinomas, while the codon 12 aspartate-for-glycine (G12D) Ras mutation shows no such association.
|
10398103 |
1999 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03).
|
15294875 |
2004 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D).
|
18098337 |
2008 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (Gly → Asp; G12D, Gly → Asp, G13D; Gly → Val; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients.
|
20162668 |
2010 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance.
|
23209813 |
2012 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer.
|
22753589 |
2012 |
rs121913238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.
|
23400451 |
2013 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far.
|
25367198 |
2014 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination.
|
24522186 |
2014 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
rs712
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25).
|
23975373 |
2014 |
rs397517040
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient.
|
24594115 |
2014 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene.
|
25359494 |
2015 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
|
25359494 |
2015 |
rs121913530
|
|
|
0.040 |
GeneticVariation |
BEFREE |
KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion.
|
26056087 |
2015 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses.
|
26662311 |
2016 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers.
|
26701267 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups.
|
27246726 |
2016 |
rs112445441
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS.
|
27805251 |
2016 |
rs121913240
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Review of colorectal carcinomas with known KRAS and NRAS genotype revealed that none of 62 wild-type tumors or 47 mutants other than Q61R were SP174 positive.
|
28353383 |
2017 |
rs61764370
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
rs1137188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In genetic polymorphisms analysis, we found that the KRAS rs1137188 variant AA genotype had higher portion of tumor size (≥ 5 cm) (P = 0.01; Bonferroni-adjusted P = 0.04), which suggested that the rs1137188 variant AA genotype may significantly be associated with increased progression of CRC.
|
28328959 |
2017 |
rs1137188
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this case-control study of 371 CRC cases and 246 healthy controls, we analyzed the association between one SNP (rs1137188G > A) in the KRAS gene and four SNPs (rs3025039C > T, rs3025040C > T, rs3025053G > A and rs10434A > G) in the VEGF gene and CRC susceptibility by the improved multiplex ligase detection reaction (iMLDR) method.
|
28328959 |
2017 |
rs121913529
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |